Table 1 Baseline patient characteristics of patients with NHL reported to the CIBMTR from 2008 to 2014
Variable | Non-rituximab-RIC N = 1022 | Rituximab-containing RIC N = 379 | p value |
|---|---|---|---|
Age at HCT, years | |||
Median (range) | 57 (18–74) | 56 (28–74) | 0.32 |
>65 | 142 (14) | 45 (12) | 0.07 |
Male gender | 667 (65) | 248 (65) | 0.95 |
Race | 0.55 | ||
Caucasian | 918 (90) | 359 (95) | |
African American | 24 (2) | 8 (2) | |
Others | 17 (2) | 10 (3) | |
Missing | 63 (6) | 2 (<1) | |
Karnofsky performance score ≥90 | 622 (61) | 235 (62) | 0.24 |
HCT-CI | 0.58 | ||
0 | 331 (32) | 141 (37) | |
1–2 | 301 (29) | 115 (30) | |
≥3 | 326 (32) | 120 (32) | |
Missing | 64 (6) | 3 (<1) | |
Histology | <0.001 | ||
Follicular lymphoma | 268 (26) | 142 (37) | |
Diffuse large B cell lymphoma | 452 (44) | 124 (33) | |
Mantle cell lymphoma | 274 (27) | 106 (28) | |
Marginal zone lymphoma | 28 (3) | 7 (2) | |
Interval from diagnosis to HCT, months | 0.73 | ||
Median (range) | 36 (2-386) | 39 (3-310) | |
Median lines of therapy before HCT | 3 (1-9) | 3 (1-8) | 0.54 |
Remission status at HCT | 0.19 | ||
Complete remission | 459 (45) | 147 (39) | |
Partial remission | 421 (41) | 169 (45) | |
Chemorefractory | 125 (12) | 59 (16) | |
Untreated | 8 (<1) | 2 (<1) | |
Unknown | 9 (<1) | 2 (<1) | |
Disease risk index at HCT | 0.003 | ||
Low | 405 (40) | 184 (49) | |
Intermediate | 509 (50) | 151 (40) | |
High | 99 (10) | 42 (11) | |
Missing | 9 (<1) | 2 (<1) | |
History of prior autologous HCT | 436 (43) | 99 (26) | <0.001 |
Conditioning regimen | <0.001 | ||
Flu/Bu ± TBI | 360 (35) | 21 (5) | |
Flu/Cy ± TBI | 156 (15) | 207 (54) | |
Flu/Mel ± TBI | 271 (27) | 55 (15) | |
2 Gy TBI ± Flu | 196 (19) | 40 (11) | |
BEAM or similar | 39 (4) | 56 (15) | |
TBI in conditioning | 265 (26) | 90 (24) | 0.40 |
ATG in conditioning | 191 (19) | 75 (20) | 0.64 |
Graft source | 0.02 | ||
Bone marrow | 52 (5) | 8 (2) | |
Peripheral blood | 970 (95) | 371 (98) | |
Donor type | 0.10 | ||
HLA-identical sibling | 565 (55) | 191 (50) | |
URD 8/8 | 457 (45) | 188 (50) | |
Donor-recipient sex match | 66 (36) | 227 (46) | 0.62 |
Male-male | 434 (42) | 168 (44) | |
Male-female | 222 (22) | 89 (23) | |
Female-male | 233 (23) | 80 (21) | |
Female-female | 133 (13) | 42 (11) | |
Donor/recipient CMV status | 0.14 | ||
Both negative | 305 (30) | 112 (30) | |
Either donor/recipient+ | 711 (70) | 259 (68) | |
Missing | 6 (<1) | 8 (2) | |
Graft-versus-host disease prophylaxis | <0.001 | ||
Calcineurin inhibitor + MTX ± othersa (except MMF and sirolimus) | 392 (38) | 207 (55) | |
Calcineurin inhibitor + MMF ± othersa (except sirolimus) | 402 (39) | 95 (25) | |
Calcineurin inhibitor + sirolimus ± othersa | 200 (20) | 75 (20) | |
Calcineurin inhibitor alone | 28 (3) | 2 (<1) | |
Median follow-up of survivors (range), months | 37 (2–79) | 47 (6–89) |